van Meer G, van 't Hof W
Department of Cell Biology, Medical School AZU H02.314, University of Utrecht, The Netherlands.
J Cell Sci. 1993 Mar;104 ( Pt 3):833-42. doi: 10.1242/jcs.104.3.833.
In epithelial MDCK and Caco-2 cells, short-chain analogs of glucosylceramide and sphingomyelin are delivered from the Golgi to the cell surface with different apical/basolateral polarities, which results in an apical enrichment of the glycolipid glucosylceramide over the phospholipid sphingomyelin. Here, we have interfered with the integrity of the Golgi complex in various ways and tested the effects on lipid transport and sorting. Nocodazole, which depolymerizes microtubules, dispersed the Golgi over the cytoplasm of MDCK cells and reduced transport of newly synthesized C6-NBD-(N-6[7-nitro-2,1,3-benzoxadiazol-4-yl]aminocaproyl)-glucosy lceramide and C6-NBD-sphingomyelin to the apical surface by 40%. The lipids were not mistargeted to the basolateral surface and upon removal of nocodazole, apical transport recovered. Nocodazole did not affect the apical enrichment of glucosylceramide over sphingomyelin. The ionophore monensin led to swelling of the Golgi of MDCK cells and inhibited lipid transport to the cell surface by 30-50%. Whereas sphingomyelin transport to both surface domains was equally affected, monensin mainly inhibited apical transport of glucosylceramide. At 10-20 microM of monensin, the two lipids displayed the same polarity of delivery: sorting between the two lipids was abolished. Brefeldin A at 1 microgram/ml, which resulted in disruption of the Golgi in HepG2 cells and completely inhibited protein secretion, had no inhibitory effect on transport of the C6-NBD-lipids to the surface. The same was observed in Caco-2 cells. However, brefeldin A selectively shifted transport of sphingomyelin towards the apical direction which abolished the apical enrichment of glucosylceramide over sphingomyelin. Caco-2 cells were used because in MDCK cells brefeldin A did not change Golgi structure nor lipid transport and sorting. In summary, modification of the Golgi by monensin and brefeldin A, but not nocodazole, interfered with the sorting event by which glucosylceramide is enriched over sphingomyelin in the transport pathway from the Golgi to the apical surface.
在上皮性MDCK细胞和Caco - 2细胞中,葡萄糖神经酰胺和鞘磷脂的短链类似物从高尔基体转运至细胞表面时具有不同的顶侧/基底外侧极性,这导致糖脂葡萄糖神经酰胺在磷脂鞘磷脂之上出现顶侧富集。在此,我们以多种方式干扰了高尔基体复合体的完整性,并测试了其对脂质转运和分选的影响。诺考达唑可使微管解聚,它使MDCK细胞胞质中的高尔基体分散,并使新合成的C6 - NBD -(N - 6[7 - 硝基 - 2,1,3 - 苯并恶二唑 - 4 - 基]氨基己酰基) - 葡萄糖神经酰胺和C6 - NBD - 鞘磷脂向顶侧表面的转运减少了40%。这些脂质并未错误靶向至基底外侧表面,去除诺考达唑后,顶侧转运得以恢复。诺考达唑并不影响葡萄糖神经酰胺相对于鞘磷脂的顶侧富集。离子载体莫能菌素导致MDCK细胞的高尔基体肿胀,并使脂质向细胞表面的转运受到30% - 50%的抑制。鞘磷脂向两个表面结构域的转运受到同等程度的影响,而莫能菌素主要抑制葡萄糖神经酰胺的顶侧转运。在10 - 20 microM的莫能菌素作用下,这两种脂质表现出相同的转运极性:两种脂质之间的分选被消除。1微克/毫升的布雷菲德菌素A导致HepG2细胞中的高尔基体破坏并完全抑制蛋白质分泌,但对C6 - NBD - 脂质向表面的转运没有抑制作用。在Caco - 2细胞中也观察到同样的情况。然而,布雷菲德菌素A使鞘磷脂的转运选择性地向顶侧方向偏移,这消除了葡萄糖神经酰胺相对于鞘磷脂的顶侧富集。使用Caco - 2细胞是因为在MDCK细胞中布雷菲德菌素A不会改变高尔基体结构以及脂质转运和分选。总之,莫能菌素和布雷菲德菌素A对高尔基体的修饰(而非诺考达唑)干扰了在从高尔基体到顶侧表面的转运途径中葡萄糖神经酰胺相对于鞘磷脂富集的分选过程。